By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) 

75 Sidney Street, 4th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-299-5000 Fax: 617-995-4995


Key Statistics

Ownership: Public

Web Site: AVEO Oncology
Symbol: AVEO


Merck & Co.  Cancer

Company News
AVEO Oncology (AVEO) To Host Conference Call To Discuss Presentation Of Final Results And Biomarker Analysis From Phase 2 Study Of Tivozanib In Patients With Advanced Colorectal Cancer 2/27/2015 10:53:27 AM
AVEO Oncology (AVEO) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/12/2015 10:25:03 AM
AVEO Oncology (AVEO) Names Michael N. Needle, M.D., As Chief Medical Officer 1/9/2015 9:42:52 AM
AVEO Oncology (AVEO) Receives Confirmation Of Eligibility For Submission Of A Tivozanib Marketing Authorization Application To European Medicines Agency 1/8/2015 11:35:41 AM
Cambridge's AVEO Oncology (AVEO) Chops Two-Thirds of Workforce 1/7/2015 6:17:14 AM
AVEO Oncology (AVEO)'s Comeback Hits a Snag as Nasdaq Warns It Could be Delisted 12/31/2014 6:10:34 AM
AVEO Oncology (AVEO), Ophthotech Corporation (OPHT) Forge Research, License Deal Worth $105 Million+ 11/11/2014 7:03:37 AM
AVEO Oncology (AVEO) Reports Third Quarter 2014 Financial Results 11/6/2014 11:00:00 AM
AVEO Oncology (AVEO) And Biodesix, Inc. Announce Exploratory Analysis Of Veristrat-Selected Patients With Non-Small Cell Lung Cancer In Phase 2 Study Of Ficlatuzumab Presented At ESMO 2014 Congress 9/29/2014 12:17:49 PM
AVEO Oncology (AVEO) Announces Results From Phase 2 Clinical Studies Of Tivozanib In Patients With Advanced Colorectal And Kidney Cancers Presented At ESMO 2014 Congress 9/29/2014 11:37:32 AM